Posted inHematology-Oncology news Oncology
Efficacy and Safety of Ziftomenib Combined with Venetoclax and Azacitidine in Relapsed/Refractory NPM1-Mutated Acute Myeloid Leukemia
This article reviews the KOMET-007 trial evaluating ziftomenib with venetoclax and azacitidine in relapsed/refractory NPM1-mutated AML, highlighting promising remission rates and manageable safety.